Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial - Takeaways - MDSpire

Effectiveness of anti-osteoporotic treatment after successful parathyroidectomy for primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial

  • By

  • Martin B. Niederle

  • Ursula Foeger-Samwald

  • Philipp Riss

  • Andreas Selberherr

  • Christian Scheuba

  • Peter Pietschmann

  • Bruno Niederle

  • Katharina Kerschan-Schindl

  • August 26, 2019

  • 0 min

Share

  • 1

    Primary hyperparathyroidism leads to decreased bone mineral density and increased fracture risk, particularly in the vertebral spine.

  • 2

    Parathyroidectomy is the only causal treatment for primary hyperparathyroidism, showing minor increases in bone mineral density post-surgery.

  • 3

    Strontium ranelate, an anti-osteoporotic medication, stimulates bone formation and reduces resorption, potentially benefiting patients post-parathyroidectomy.

  • 4

    The study investigates the effects of anti-osteoporotic treatment on bone mineral density and metabolism in patients with osteoporosis after parathyroidectomy.

  • 5

    Biochemical markers SOST and DKK-1 are analyzed as potential future targets for stimulating bone formation after successful parathyroidectomy.

Original Source(s)

Related Content